Wu Jinzi Jason 4
4 · Sagimet Biosciences Inc. · Filed Jul 20, 2023
Insider Transaction Report
Form 4
Wu Jinzi Jason
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−23,216→ 0 totalExercise: $6.36Exp: 2029-04-27→ Common Stock (23,216 underlying) - Award
Stock Option (Right to Buy)
2023-07-18+23,216→ 23,216 totalExercise: $6.36Exp: 2029-04-27→ Series A Common Stock (23,216 underlying) - Conversion
Series A Common Stock
2023-07-18+1,654,701→ 1,654,701 total(indirect: By AP11 Limited) - Conversion
Series E Preferred Stock
2023-07-18−108,471,634→ 0 total(indirect: By AP11 Limited)→ Series A Common Stock (1,364,793 underlying) - Conversion
Series F Preferred Stock
2023-07-18−23,041,474→ 0 total(indirect: By AP11 Limited)→ Series A Common Stock (289,908 underlying)
Footnotes (4)
- [F1]Upon closing of the Issuer's initial public offering, each share of Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date.
- [F2]Shares held directly by AP11 Limited, a subsidiary of Ascletis Pharma Inc. ("Ascletis"). The Reporting Person is founder, chairman and chief executive officer of Ascletis. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
- [F3]Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
- [F4]The shares underlying this option are fully vested and exercisable as of the date hereof.